Authors' objectives: The objective of this mini HTA is to review and summarize the most recent evidence on efficacy and safety of all three technologies for the diagnosis and staging of lung cancer. We also report on the budget impact of these technologies to the MUHC.

Authors' recommendations: There is sufficient evidence supporting the use of linear EBUS as a first-line approach for lung cancer staging. - For investigation of peripheral nodules suspected of lung cancer, radial EBUS should be available for use at the clinician's discretion. - There is very limited evidence supporting the usage of ENB together with R-EBUS. Therefore, this technology should be judiciously used only when the yield of radial EBUS is felt to be lower than usual and TTNA is best avoided. - Given the residual uncertainty in patient selection and the low quality of evidence on efficacy, particularly for R-EBUS and ENB technologies, it is recommended that a prospective database be maintained that will allow the study of patient characteristics and patient outcomes that can aid decision making. Such a database has been commenced for ENB at the MUHC and should be extended to include R-EBUS and L-EBUS.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.mcgill.ca/tau/files/tau/muhc_tau_2016_74_ebus_enb.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Technology Assessment Unit of the McGill University Health Centre (MUHC)

Contact Address: Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5

Contact Name: nandini.dendukuri@mcgill.ca

Contact Email: nandini.dendukuri@mcgill.ca

Copyright: Technology Assessment Unit of the McGill University Health Centre (MUHC)